CA-CEPTON-TECHNOLOGIES
19.8.2021 15:02:13 CEST | Business Wire | Press release
Leading lidar solutions provider Cepton received two recognitions at Tech.AD Europe this year for its innovations, adding to the company’s growing portfolio of award-winning lidar solutions across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005247/en/
Tech.AD is a leading technical conference in Europe focused on technologies for autonomous driving (AD) and the advancements of artificial intelligence (AI) technology in the automotive industry. The annual Tech.AD Europe Award exclusively honors "extraordinary projects in the automotive industry and celebrates exceptional solutions & innovations." Awards are announced after submissions are rated by a jury of some of the top subject matter experts in Europe.
Cepton was recognized in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies for its Nova lidar . Second place award-winner in this category, Nova is a pathbreaking miniature, wide field of view (FOV) lidar sensor for near-range perception in advanced driver assistance systems (ADAS), autonomous vehicle (AV) and autonomous ground vehicle (AGV) applications. Nova provides an attractive combination of performance, compactness, FOV coverage and affordability and enables a range of use cases such as high-accuracy blind spot detection, small object detection, automated park assist and free space estimation around the vehicle.
Another award was given to a Cepton lidar-enabled smart cities project - Traffic Monitoring as Source of Training Data for Autonomous Vehicles - by Cepton partner ALP.Lab , which won the top prize in the category of Most Advanced Real-Life Testing & Simulation Techniques in Autonomous Driving . Deployed in the City of Graz, the ALP.Lab project utilizes Cepton’s Helius ® Smart Lidar System and Vista® -P lidars to enable advanced, real-time, 3D traffic and pedestrian analytics. According to ALP.Lab, “the enormous amount of time and expense involved in collecting training data for ADAS/AD development can be dramatically reduced by this new and sustainable lidar perception based technique focused on specific roads and environments likely to generate the most diverse and difficult driving environments.”
The Tech.AD Europe awards represent a continuation of past recognitions of Cepton’s lidar innovations. Previously, Cepton received awards for its lidar solutions across multiple applications, including the AUVSI XCELLENCE in Innovation Award in 2019 for the Sora™ lidar, the Security Today New Product of the Year Award in 2019 in the Perimeter Protection category for the first generation of Helius® known as Vista-Edge, the Autonomous Vehicle Technology ACES Award in 2020 jointly with Cepton partner Dataspeed for the Vista® -P lidar, and the CES Innovation Award in 2020 in two categories – Smart Cities and Tech for a Better World – for the Helius® Smart Lidar system, that also includes our Vista® -P lidars.
Dr. Jun Pei, CEO of Cepton, said: “The awards at Tech.AD Europe were not only based on jury selection, but also based on the voting of all of the conference attendees representing leading automotive OEMs, autonomous vehicle companies, Tier 1 suppliers, and other R&D organizations worldwide. We are grateful for this recognition and what it represents for the continued innovation we are bringing to market using our MMT® lidar technology. Increasingly, the role of Cepton lidars in the future of mobility is becoming clear worldwide and we are pleased to work with global partners such as ALP.Lab in advancing safety and autonomy.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in North America, Germany, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom